Hologic to Acquire Biolucent
By MedImaging staff writers Posted on 12 Jul 2007 |
Hologic, Inc. (Bedford, MA, USA), a leading provider of diagnostic imaging and digital imaging systems directed towards women's health, has entered into a definitive agreement to acquire BioLucent, Inc. (Aliso Viejo, CA, USA) and its MammoPad breast cushion business. Concurrently with the closing of the transaction, Biolucent will spin-off its brachytherapy business into a newly created company, which will remain an independent company.
The purchase price will be US$70 million (subject to reduction in certain circumstances), plus a two-year earn out. The closing consideration will consist of $5 million in cash and an additional $65 million payable, at the election of Hologic, in cash, shares of Hologic Common Stock or a combination thereof.
BioLucent, is a privately held medical device company that designed, manufactures, and markets the MammoPad breast cushion, a radiolucent foam cushion that covers the cold, hard surfaces of all commercially available mammography equipment. BioLucent's patented MammoPad is designed to reduce the discomfort that inhibits many women from getting routine mammography screenings. MammoPad is offered as standard of care in nearly 20% of mammography facilities in the United States and has been used by more than 10 million women.
"Expanding our market share in women's health is a key element in the growth of our company,” said Jack Cumming, chairman and chief executive officer. "The acquisition of this technology is consistent with the company's strategy of looking to the future and building upon our established technology roadmap. We believe this acquisition provides us additional technical capabilities and customer relationships to further solidify our position of strength in the growing mammography market.”
Hologic is a leading developer, manufacturer, and supplier of diagnostic and medical imaging systems designed to serve the healthcare needs of women, and a leading developer of innovative imaging technology for digital radiography and breast imaging. Hologic's core business units are focused on mammography and breast biopsy, osteoporosis assessment, and mini C-arm and extremity magnetic resonance imaging (MRI) imaging for orthopedic applications.
BioLucent is a women's health company dedicated to the early detection of breast cancer. The company's MammoPad breast cushion reduces mammography discomfort while also ensuring high-quality images.
Related Links:
Hologic
BioLucent
The purchase price will be US$70 million (subject to reduction in certain circumstances), plus a two-year earn out. The closing consideration will consist of $5 million in cash and an additional $65 million payable, at the election of Hologic, in cash, shares of Hologic Common Stock or a combination thereof.
BioLucent, is a privately held medical device company that designed, manufactures, and markets the MammoPad breast cushion, a radiolucent foam cushion that covers the cold, hard surfaces of all commercially available mammography equipment. BioLucent's patented MammoPad is designed to reduce the discomfort that inhibits many women from getting routine mammography screenings. MammoPad is offered as standard of care in nearly 20% of mammography facilities in the United States and has been used by more than 10 million women.
"Expanding our market share in women's health is a key element in the growth of our company,” said Jack Cumming, chairman and chief executive officer. "The acquisition of this technology is consistent with the company's strategy of looking to the future and building upon our established technology roadmap. We believe this acquisition provides us additional technical capabilities and customer relationships to further solidify our position of strength in the growing mammography market.”
Hologic is a leading developer, manufacturer, and supplier of diagnostic and medical imaging systems designed to serve the healthcare needs of women, and a leading developer of innovative imaging technology for digital radiography and breast imaging. Hologic's core business units are focused on mammography and breast biopsy, osteoporosis assessment, and mini C-arm and extremity magnetic resonance imaging (MRI) imaging for orthopedic applications.
BioLucent is a women's health company dedicated to the early detection of breast cancer. The company's MammoPad breast cushion reduces mammography discomfort while also ensuring high-quality images.
Related Links:
Hologic
BioLucent
Latest Industry News News
- GE HealthCare and NVIDIA Collaboration to Reimagine Diagnostic Imaging
- Patient-Specific 3D-Printed Phantoms Transform CT Imaging
- Siemens and Sectra Collaborate on Enhancing Radiology Workflows
- Bracco Diagnostics and ColoWatch Partner to Expand Availability CRC Screening Tests Using Virtual Colonoscopy
- Mindray Partners with TeleRay to Streamline Ultrasound Delivery
- Philips and Medtronic Partner on Stroke Care
- Siemens and Medtronic Enter into Global Partnership for Advancing Spine Care Imaging Technologies
- RSNA 2024 Technical Exhibits to Showcase Latest Advances in Radiology
- Bracco Collaborates with Arrayus on Microbubble-Assisted Focused Ultrasound Therapy for Pancreatic Cancer
- Innovative Collaboration to Enhance Ischemic Stroke Detection and Elevate Standards in Diagnostic Imaging
- RSNA 2024 Registration Opens
- Microsoft collaborates with Leading Academic Medical Systems to Advance AI in Medical Imaging
- GE HealthCare Acquires Intelligent Ultrasound Group’s Clinical Artificial Intelligence Business
- Bayer and Rad AI Collaborate on Expanding Use of Cutting Edge AI Radiology Operational Solutions
- Polish Med-Tech Company BrainScan to Expand Extensively into Foreign Markets
- Hologic Acquires UK-Based Breast Surgical Guidance Company Endomagnetics Ltd.
Channels
Radiography
view channel
Machine Learning Algorithm Identifies Cardiovascular Risk from Routine Bone Density Scans
A new study published in the Journal of Bone and Mineral Research reveals that an automated machine learning program can predict the risk of cardiovascular events and falls or fractures by analyzing bone... Read more
AI Improves Early Detection of Interval Breast Cancers
Interval breast cancers, which occur between routine screenings, are easier to treat when detected earlier. Early detection can reduce the need for aggressive treatments and improve the chances of better outcomes.... Read more
World's Largest Class Single Crystal Diamond Radiation Detector Opens New Possibilities for Diagnostic Imaging
Diamonds possess ideal physical properties for radiation detection, such as exceptional thermal and chemical stability along with a quick response time. Made of carbon with an atomic number of six, diamonds... Read moreMRI
view channel
Simple Brain Scan Diagnoses Parkinson's Disease Years Before It Becomes Untreatable
Parkinson's disease (PD) remains a challenging condition to treat, with no known cure. Though therapies have improved over time, and ongoing research focuses on methods to slow or alter the disease’s progression,... Read more
Cutting-Edge MRI Technology to Revolutionize Diagnosis of Common Heart Problem
Aortic stenosis is a common and potentially life-threatening heart condition. It occurs when the aortic valve, which regulates blood flow from the heart to the rest of the body, becomes stiff and narrow.... Read moreUltrasound
view channel
New Incision-Free Technique Halts Growth of Debilitating Brain Lesions
Cerebral cavernous malformations (CCMs), also known as cavernomas, are abnormal clusters of blood vessels that can grow in the brain, spinal cord, or other parts of the body. While most cases remain asymptomatic,... Read more.jpeg)
AI-Powered Lung Ultrasound Outperforms Human Experts in Tuberculosis Diagnosis
Despite global declines in tuberculosis (TB) rates in previous years, the incidence of TB rose by 4.6% from 2020 to 2023. Early screening and rapid diagnosis are essential elements of the World Health... Read moreNuclear Medicine
view channel
New Imaging Approach Could Reduce Need for Biopsies to Monitor Prostate Cancer
Prostate cancer is the second leading cause of cancer-related death among men in the United States. However, the majority of older men diagnosed with prostate cancer have slow-growing, low-risk forms of... Read more
Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors
Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor commonly found in solid tumors such as glioblastoma, melanoma, and breast cancer. It is minimally expressed in normal tissues, making it... Read moreGeneral/Advanced Imaging
view channel
First-Of-Its-Kind Wearable Device Offers Revolutionary Alternative to CT Scans
Currently, patients with conditions such as heart failure, pneumonia, or respiratory distress often require multiple imaging procedures that are intermittent, disruptive, and involve high levels of radiation.... Read more
AI-Based CT Scan Analysis Predicts Early-Stage Kidney Damage Due to Cancer Treatments
Radioligand therapy, a form of targeted nuclear medicine, has recently gained attention for its potential in treating specific types of tumors. However, one of the potential side effects of this therapy... Read moreImaging IT
view channel
New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more